Back to Search Start Over

Recommended vaccinations for asplenic and hyposplenic adult patients

Authors :
Paolo Bonanni
Maddalena Grazzini
Giuditta Niccolai
Diana Paolini
Ornella Varone
Alessandro Bartoloni
Filippo Bartalesi
Maria Grazia Santini
Simonetta Baretti
Carlo Bonito
Paola Zini
Maria Teresa Mechi
Fabrizio Niccolini
Lea Magistri
Maria Beatrice Pulci
Sara Boccalini
Angela Bechini
Source :
Human Vaccines & Immunotherapeutics, Vol 13, Iss 2, Pp 359-368 (2017)
Publication Year :
2017
Publisher :
Taylor & Francis Group, 2017.

Abstract

Asplenic or hyposplenic (AH) individuals are particularly vulnerable to invasive infections caused by encapsulated bacteria. Such infections have often a sudden onset and a fulminant course. Infectious diseases (IDs) incidence in AH subjects can be reduced by preventive measures such as vaccination. The aim of our work is to provide updated recommendations on prevention of infectious diseases in AH adult patients, and to supply a useful and practical tool to healthcare workers for the management of these subjects, in hospital setting and in outpatients consultation. A systematic literature review on evidence based measures for the prevention of IDs in adult AH patients was performed in 2015. Updated recommendations on available vaccines were consequently provided. Vaccinations against S. pneumoniae, N. meningitidis, H. influenzae type b and influenza virus are strongly recommended and should be administered at least 2 weeks before surgery in elective cases or at least 2 weeks after the surgical intervention in emergency cases. In subjects without evidence of immunity, 2 doses of live attenuated vaccines against measles-mumps-rubella and varicella should be administered 4–8 weeks apart from each other; a booster dose of tetanus, diphtheria and pertussis vaccine should be administered also to subjects fully vaccinated, and a 3-dose primary vaccination series is recommended in AH subjects with unknown or incomplete vaccination series (as in healthy people). Evidence based prevention data support the above recommendations to reduce the risk of infection in AH individuals.

Details

Language :
English
ISSN :
21645515 and 2164554X
Volume :
13
Issue :
2
Database :
Directory of Open Access Journals
Journal :
Human Vaccines & Immunotherapeutics
Publication Type :
Academic Journal
Accession number :
edsdoj.fefcbf50d1340219206598bd74e9267
Document Type :
article
Full Text :
https://doi.org/10.1080/21645515.2017.1264797